Fosun Pharma-backed C.Q.Pharmaceutical Holding Co., Ltd (CQP) has agreed to buy out biological medicine player Tasly Holding Group’s subsidiary Tasly Pharmaceuticals Inc for as much as 1.489 billion yuan ($210 million), according to a company filing with Shenzhen Stock Exchange.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
